Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance

Clin Pharmacol Ther. 2024 May;115(5):954-964. doi: 10.1002/cpt.3213. Epub 2024 Mar 8.

Abstract

The clinical benefits of statins have well-established and recognized worldwide. Although statins are well-tolerated generally, however, the report of statin-related adverse event and statin intolerance are common in China, which results in insufficient use of statins and poor adherence. The main reason may be attributed to confusions or misconceptions in the clinical diagnosis and management in China, including the lack of unified definitions and diagnostic standards, broad grasp of diagnosis, and unscientific management strategies. Based on that, this consensus carefully summarized the statin-related gene polymorphism and statin usage issue among Chinese population, and comprehensively reviewed global research data on statin intolerance, referenced guidelines, and consensus literature on statin intolerance in foreign and different regions, proposes an appropriate and easy to implement statin intolerance definition as well as corresponding diagnostic criteria and management strategies for Chinese clinicians, in order to improve the clinical application of statin drugs and enhance the prevention and treatment level of atherosclerotic cardiovascular disease in China.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases* / prevention & control
  • China / epidemiology
  • Consensus
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors